| Tumor mutational burden and response rate to PD-1 inhibition M Yarchoan, A Hopkins, EM Jaffee New England Journal of Medicine 377 (25), 2500-2501, 2017 | 2858 | 2017 |
| Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic TA Chan, M Yarchoan, E Jaffee, C Swanton, SA Quezada, A Stenzinger, ... Annals of Oncology 30 (1), 44-56, 2019 | 2108 | 2019 |
| Targeting neoantigens to augment antitumour immunity M Yarchoan, BA Johnson III, ER Lutz, DA Laheru, EM Jaffee Nature Reviews Cancer 17 (4), 209-222, 2017 | 1001 | 2017 |
| PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers M Yarchoan, LA Albacker, AC Hopkins, M Montesion, K Murugesan, ... JCI insight 4 (6), 2019 | 440 | 2019 |
| AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma AG Singal, JM Llovet, M Yarchoan, N Mehta, JK Heimbach, LA Dawson, ... Hepatology 78 (6), 1922-1965, 2023 | 360 | 2023 |
| Cerebrovascular atherosclerosis correlates with Alzheimer pathology in neurodegenerative dementias M Yarchoan, SX Xie, MA Kling, JB Toledo, DA Wolk, EB Lee, ... Brain 135 (12), 3749-3756, 2012 | 309 | 2012 |
| Repurposing diabetes drugs for brain insulin resistance in Alzheimer disease M Yarchoan, SE Arnold Diabetes 63 (7), 2253-2261, 2014 | 263 | 2014 |
| T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma AC Hopkins, M Yarchoan, JN Durham, EC Yusko, JA Rytlewski, ... JCI insight 3 (13), 2018 | 222 | 2018 |
| Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors A Diehl, M Yarchoan, A Hopkins, E Jaffee, SA Grossman Oncotarget 8 (69), 114268, 2017 | 214 | 2017 |
| Programmed cell death ligand-1 (PD-L1) and CD8 expression profiling identify an immunologic subtype of pancreatic ductal adenocarcinomas with favorable survival L Danilova, WJ Ho, Q Zhu, T Vithayathil, A De Jesus-Acosta, NS Azad, ... Cancer immunology research 7 (6), 886-895, 2019 | 202 | 2019 |
| Abnormal serine phosphorylation of insulin receptor substrate 1 is associated with tau pathology in Alzheimer’s disease and tauopathies M Yarchoan, JB Toledo, EB Lee, Z Arvanitakis, H Kazi, LY Han, ... Acta neuropathologica 128, 679-689, 2014 | 197 | 2014 |
| Tumour mutational burden as a biomarker for immunotherapy: current data and emerging concepts JD Fumet, C Truntzer, M Yarchoan, F Ghiringhelli European Journal of Cancer 131, 40-50, 2020 | 182 | 2020 |
| Strategies for increasing pancreatic tumor immunogenicity BA Johnson III, M Yarchoan, V Lee, DA Laheru, EM Jaffee Clinical Cancer Research 23 (7), 1656-1669, 2017 | 152 | 2017 |
| Neuroprotective effects of the amylin analogue pramlintide on Alzheimer's disease pathogenesis and cognition BL Adler, M Yarchoan, HM Hwang, N Louneva, JA Blair, R Palm, ... Neurobiology of aging 35 (4), 793-801, 2014 | 149 | 2014 |
| Combining STING-based neoantigen-targeted vaccine with checkpoint modulators enhances antitumor immunity in murine pancreatic cancer HL Kinkead, A Hopkins, E Lutz, AA Wu, M Yarchoan, K Cruz, S Woolman, ... JCI insight 3 (20), 2018 | 143 | 2018 |
| Immuno-oncology trial endpoints: capturing clinically meaningful activity V Anagnostou, M Yarchoan, AR Hansen, H Wang, F Verde, E Sharon, ... Clinical Cancer Research 23 (17), 4959-4969, 2017 | 142 | 2017 |
| Recent developments and therapeutic strategies against hepatocellular carcinoma M Yarchoan, P Agarwal, A Villanueva, S Rao, LA Dawson, T Karasic, ... Cancer research 79 (17), 4326-4330, 2019 | 138 | 2019 |
| Characterization of the immune microenvironment in hepatocellular carcinoma M Yarchoan, D Xing, L Luan, H Xu, RB Sharma, A Popovic, TM Pawlik, ... Clinical Cancer Research 23 (23), 7333-7339, 2017 | 135 | 2017 |
| Neoadjuvant cabozantinib and nivolumab converts locally advanced HCC into resectable disease with enhanced antitumor immunity. WJ Ho, Q Zhu, J Durham, A Popovic, S Xavier, J Leatherman, A Mohan, ... Nature cancer 2 (9), 891-903, 2021 | 133 | 2021 |
| Pan-tumor pathologic scoring of response to PD-(L) 1 blockade JE Stein, EJ Lipson, TR Cottrell, PM Forde, RA Anders, ... Clinical Cancer Research 26 (3), 545-551, 2020 | 109 | 2020 |
Nilofer S AzadJohns Hopkins University在 jhmi.edu 的电子邮件经过验证
